{"filings":[{"id":91128,"accession_number":"0001077183-26-000022","cik":1077183,"company_name":"NEOGENOMICS INC","ticker":"NEO","form_type":"8-K","filed_at":"2026-04-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NeoGenomics Q1 revenue up 11% to $187M; raises FY2026 guidance to $797-803M","event_type":"earnings","confidence":"high","bullets":["Consolidated revenue $187M (+11% YoY); Clinical revenue +14%, NGS +26%.","Net loss narrowed 34% to $17M; adjusted EBITDA $9M (+27% YoY).","Raised FY2026 revenue guidance to $797-803M (prior range not specified).","Launched RaDaR ST MRD assay; received MolDX coverage for PanTracer LBx.","Cash and marketable securities $146M at quarter end."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":186672000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.78,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101047,"accession_number":"0001077183-26-000004","cik":1077183,"company_name":"NEOGENOMICS INC","ticker":"NEO","form_type":"8-K","filed_at":"2026-02-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NeoGenomics Q4 revenue up 11% to $190M; full-year net loss widens to $108M; RaDaR ST MRD launch imminent","event_type":"earnings","confidence":"high","bullets":["Q4 consolidated revenue $190M (+11% YoY); full-year revenue $727M (+10% YoY); clinical revenue grew 15% excluding Pathline.","Q4 net loss decreased 36% to $10M; full-year net loss increased 37% to $108M; Adjusted EBITDA positive $13M (Q4) and $43M (FY).","Clinical NGS volumes grew 23% in Q4 and 22% for full year, outpacing market growth.","RaDaR ST MRD assay imminent clinical launch; company addresses $20B+ MRD monitoring market; modest 2026 revenue expected.","Successfully resolved RaDaR ST patent litigation (no financial details disclosed)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":727332000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101046,"accession_number":"0001628280-26-001746","cik":1077183,"company_name":"NEOGENOMICS INC","ticker":"NEO","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"NeoGenomics prelim Q4 rev $190M (+11% YoY), FY rev $727M (+10%); CFO Sherman retiring, Jain appointed","event_type":"other_material","confidence":"high","bullets":["Preliminary Q4 2025 revenue ~$190M (+11% YoY); full-year 2025 revenue ~$727M (+10% YoY).","CFO Jeff Sherman to retire; will become EVP Finance on March 2, 2026, then special adviser through April 2028.","Abhishek Jain joins as EVP Finance Jan 12, 2026; to assume CFO role on March 2, 2026.","Jain's compensation: base salary $520K, target bonus 60% of salary, initial equity grant $2.75M (RSUs and options).","Results are preliminary and subject to change; final results expected in February 2026 earnings call."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117393,"accession_number":"0001628280-25-059067","cik":1077183,"company_name":"NEOGENOMICS INC","ticker":"NEO","form_type":"8-K","filed_at":"2025-12-30T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"NeoGenomics appoints Jack Kenny to board; Dr. Alison Hannah departs after 10 years","event_type":"leadership","confidence":"high","bullets":["Dr. Alison Hannah resigns from NeoGenomics board effective Dec 31, 2025, after over 10 years of service.","Jack Kenny appointed to board effective Jan 1, 2026; former CEO of Meridian Bioscience (taken private 2023).","Mr. Kenny brings 30+ years of diagnostics and lab services experience; also serves on Orasure, DCN, Quantum-SI boards.","Mr. Kenny's compensation is consistent with NeoGenomics' director compensation plan as disclosed in 2025 proxy.","No related-party transactions involving Mr. Kenny requiring disclosure under Item 404(a)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117392,"accession_number":"0001077183-25-000172","cik":1077183,"company_name":"NEOGENOMICS INC","ticker":"NEO","form_type":"8-K","filed_at":"2025-10-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NeoGenomics Q3 revenue up 12% to $188M; net loss widens 53% to $27M","event_type":"earnings","confidence":"high","bullets":["Revenue of $188M, +12% YoY; clinical revenue +18% and NGS +24% to ~1/3 of clinical.","Net loss $27M vs $18M, up 53%; adjusted EBITDA $12.2M, down 9% from $13.4M.","Reaffirmed FY 2025 guidance: revenue $720-726M, net loss $(116)-(108)M, adj EBITDA $41-44M.","OpEx +12% YoY, includes $7.1M impairment charge on Trapelo held-for-sale."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":537162000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133811,"accession_number":"0001077183-25-000162","cik":1077183,"company_name":"NEOGENOMICS INC","ticker":"NEO","form_type":"8-K","filed_at":"2025-08-08T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Elizabeth Floegel resigns from NeoGenomics Board effective August 5, 2025","event_type":"leadership","confidence":"high","bullets":["Elizabeth Floegel resigned from the Board of Directors effective August 5, 2025.","Resignation not due to any disagreement with the Company on operations, policies, or practices.","No replacement has been announced; Board size reduced accordingly."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133810,"accession_number":"0001077183-25-000151","cik":1077183,"company_name":"NEOGENOMICS INC","ticker":"NEO","form_type":"8-K","filed_at":"2025-07-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NeoGenomics Q2 revenue up 10% to $181M but net loss widens to $45M; cuts full-year guidance","event_type":"earnings","confidence":"high","bullets":["Revenue $181M (+10% YoY); clinical revenue grew 16% (13% ex-Pathline).","Net loss widened 142% to $45M including $20M impairment charges.","Adjusted EBITDA flat at $10.7M vs $10.9M last year.","Full-year 2025 revenue guidance cut to $720-$726M (prev $747-$759M); Adj EBITDA guidance lowered to $41-$44M.","Acquired Pathline for $8M cash plus $1M contingent consideration in April 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":349365000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150544,"accession_number":"0001077183-25-000145","cik":1077183,"company_name":"NEOGENOMICS INC","ticker":"NEO","form_type":"8-K","filed_at":"2025-06-24T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"NeoGenomics appoints Merck oncology head Dr. Marjorie Green to board","event_type":"leadership","confidence":"high","bullets":["Dr. Marjorie C. Green appointed to NeoGenomics board effective June 19, 2025; board expands from 9 to 10 members.","Dr. Green is SVP and Head of Oncology, Global Clinical Development at Merck, leading oncology R&D for Merck's largest revenue area.","Prior leadership roles include SVP Late-Stage Development at Seagen and VP at Genentech; began career as medical oncologist at MD Anderson.","She will serve as an independent director until the 2026 annual meeting; compensation follows standard director program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150543,"accession_number":"0001077183-25-000109","cik":1077183,"company_name":"NEOGENOMICS INC","ticker":"NEO","form_type":"8-K","filed_at":"2025-05-27T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"NeoGenomics shareholders approve 4.325M share increase to 2023 Equity Plan, all directors re-elected","event_type":"other_material","confidence":"high","bullets":["Amendment to 2023 Equity Incentive Plan approved: +4.325M shares, 1-year minimum vesting, no liberal share recycling.","All nine director nominees elected; votes ranged from 93.7% to 99.1% support (excluding broker non-votes).","Advisory say-on-pay passed with 81.77% of votes cast; board adopted annual frequency for future votes.","Ratification of Deloitte & Touche as auditor received 99.86% of votes cast."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}